Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Emergent BioSolutions Clear all

Conditions: Anthrax Infection
Interventions: AVA, Ad4-PA-1, Ad4-PA-GPI-1; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Kansas City, Kansas • Silver Spring, Maryland • St Louis, Missouri + 1 more

Conditions: Typhoid
Interventions: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: South Miami, Florida • Baltimore, Maryland • Burlington, Vermont

Conditions: Smallpox
Interventions: Not listed
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 17 Years and older
Enrollment: 14,108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Twentynine Palms, California • Fort Campbell North, Kentucky • Fort Bliss, Texas + 1 more

Conditions: SARS-CoV-2 Infection
Interventions: COVID-HIG; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: Viral Infection
Interventions: UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Smallpox
Interventions: Not listed
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 17 Years and older
Enrollment: 5,001 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Healthy Volunteers
Interventions: Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Loma Linda, California • Yakima, Washington

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 3,258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 47
States / cities: Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more

Conditions: Chikungunya Virus Infection
Interventions: CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 445 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Lenexa, Kansas • Kansas City, Missouri • West Jordan, Utah

Conditions: Anthrax
Interventions: BioThrax; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Miami, Florida • Rochester, New York • Mt. Pleasant, South Carolina + 1 more

Conditions: Cholera
Interventions: PXVX0200, placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Burlington, Vermont

Conditions: Anthrax
Interventions: AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg, Gamunex 180 mg/kg, AIGIV 14.0 mg/kg, Gamunex 360 mg/kg; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Typhoid Fever
Interventions: Vivotif; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Smallpox
Interventions: Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 29 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 4
States / cities: Orlando, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more

Conditions: Infections, Bacterial
Interventions: AVA, Raxibacumab, Diphenhydramine; Biological · Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 573 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee

Conditions: Chikungunya Virus
Interventions: CHIKV VLP, adjuvanted; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Bird Flu, Influenza
Interventions: Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1; Other · Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more

Conditions: Cholera
Interventions: PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 3,146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more

Conditions: Healthy Volunteer, HIV Vaccine
Interventions: Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Opioid Overdose
Interventions: 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray; Combination Product
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Zika Virus, Zika Virus Infection
Interventions: VLA1601, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Chikungunya
Interventions: Chikungunya; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Fort Deterick, Maryland • Silver Spring, Maryland

Conditions: Anthrax
Interventions: AVP-21D9, Placebo; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anthrax
Interventions: AV7909, BioThrax; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more

Search by objective public record fields.

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels